Otsuka Quantifies Generic Abilify Hit, Mourns President
This article was originally published in PharmAsia News
Otsuka Pharmaceutical has been rocked by the sudden death of its president at a young age, losing one of the more colorful characters in the Japanese pharma industry at what is a challenging time for the company, which outlined for the first time the impact it expects from generic Abilify in the U.S.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.